Resumen
Definición
MM is a malignant neoplasm of plasma cells. Myeloma cells proliferate and accumulate in the bone marrow and secrete abnormal (monoclonal) immunoglobulins or immunoglobulin fragments (known as a paraprotein or M-protein). This can result in complications such as hypercalcemia, osteolytic bone disease, renal failure, anemia, and infection.[1][2] [Figure caption and citation for the preceding image starts]: A: serum protein electrophoresis demonstrating a monoclonal immunoglobulin. B: serum and urine immunofixation electrophoresis (IFE) demonstrating a monoclonal immunoglobulin and free light chain (Bence Jones [BJ] protein)Courtesy of Dr M Murali and the Clinical Immunology Laboratory, Massachusetts General Hospital; used with permission [Citation ends].
Anamnesis y examen
Principales factores de diagnóstico
- anemia
- bone pain
- monoclonal gammopathy of undetermined significance (MGUS)
Otros factores de diagnóstico
- hypercalcemia
- infections
- fatigue
- renal impairment
Factores de riesgo
- monoclonal gammopathy of undetermined significance (MGUS)
- abnormal free light-chain ratio
- male sex
- black ethnicity
- family history of MM
- radiation exposure
- petroleum products exposure
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- serum quantitative immunoglobulins
- serum/urine protein electrophoresis
- serum/urine immunofixation
- serum free light-chain assay
- whole-body low-dose CT (WBLD-CT)
- whole-body 18F-fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT)
- bone marrow evaluation
- serum calcium
- CBC with differential
- peripheral blood smear
- serum creatinine, BUN, electrolytes
- serum uric acid
- liver function tests
- C-reactive protein (CRP)
- serum lactate dehydrogenase (LDH)
- serum beta2-microglobulin
- serum albumin
- N-terminal prohormone of brain natriuretic peptide (NT-proBNP) or BNP
Pruebas diagnósticas que deben considerarse
- whole-body MRI
- skeletal survey
- cytogenetic analysis
- mass spectrometry
- genetic testing
- serum viscosity
- viral infection screening
- clonotype identification
- renal biopsy
Algoritmo de tratamiento
newly diagnosed transplant candidates
newly diagnosed nontransplant candidates
patients responding to initial treatment
relapsing or refractory disease
Colaboradores
Autores
Matthew M. Lei, PharmD
Clinical Pharmacist Medical Oncology
Massachusetts General Hospital
Boston
MA
Divulgaciones
MML has received honoraria for consultancy and speaker fees from Genentech and MJH Life Sciences, and for consultancy from Genmab, Astra Zeneca, CX4D, SERB Pharmaceuticals, and Sanofi. MML is an author of a reference cited in this topic.
Diana Cirstea, MD
Medical Oncologist
Center for Multiple Myeloma
Massachusetts General Hospital
Harvard Medical School
Boston
MA
Divulgaciones
DC is on the advisory board for Sanofi.
E. Bridget Kim, PharmD, BCPS, BCOP
Clinical Pharmacist
Massachusetts General Hospital
Boston
MA
Divulgaciones
EBK declares that she has no competing interests.
Noopur Raje, MD
Director of Multiple Myeloma Program
Massachusetts General Hospital
Harvard Medical School
Boston
MA
Divulgaciones
NR has served on steering committees for Amgen and Roche; has held membership on an entity's boards of directors or advisory committees for Novartis, Takeda Pharmaceuticals USA Inc, Merck, Celgene, Onyx Pharmaceuticals, Immuneel Therapeutics, Bristol Myers Squibb, Janssen Biotech, Caribou Biosciences, and Bluebirdbio; and has received research funding from Bluebirdbio. NR is an author of several references cited in this topic.
Agradecimientos
Dr Matthew M. Lei, Dr Diana Cirstea, Dr E. Bridget Kim, and Dr Noopur Raje would like to gratefully acknowledge Dr Loredana Santo and Dr Sonia Vallet, previous contributors to this topic.
Divulgaciones
LS and SV declare that they have no competing interests.
Revisores por pares
Shaji Kumar, MD
Associate Professor of Medicine
Mayo Clinic
Rochester
MN
Divulgaciones
SK declares that he has no competing interests.
Faith Davies, MD
Institute of Cancer Research
Sutton
Surrey
UK
Divulgaciones
FD declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referencias
Artículos principales
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48.Texto completo Resumen
Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Ann Oncol. 2021 Mar;32(3):309-22.Texto completo Resumen
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma [internet publication].Texto completo
Sive J, Cuthill K, Hunter H, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021 Apr;193(2):245-68.Texto completo Resumen
Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019 May 10;37(14):1228-63.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Monoclonal gammopathy of undetermined significance
- Solitary plasmacytoma
- Waldenström macroglobulinemia
Más DiferencialesGuías de práctica clínica
- NCCN clinical practice guidelines in oncology: multiple myeloma
- NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation
Más Guías de práctica clínicaPatient information
Multiple myeloma
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer